Soluble interleukin-6 receptor in patients with V617F somatic mutation and myeloproliferative neoplasm.
作者信息
Garbers Christoph, Rose-John Stefan
机构信息
Department of Pathology, Medical Faculty, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany.
Institute of Biochemistry, Kiel University, Kiel, Germany.
出版信息
EClinicalMedicine. 2020 May 3;22:100340. doi: 10.1016/j.eclinm.2020.100340. eCollection 2020 May.
Abstract
摘要
相似文献
1
Soluble interleukin-6 receptor in patients with V617F somatic mutation and myeloproliferative neoplasm.伴有V617F体细胞突变和骨髓增殖性肿瘤患者的可溶性白细胞介素-6受体
EClinicalMedicine. 2020 May 3;22:100340. doi: 10.1016/j.eclinm.2020.100340. eCollection 2020 May.
2
Loss-of-function polymorphism in reduces risk of V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study.中的功能丧失多态性降低V617F体细胞突变和骨髓增殖性肿瘤的风险：一项孟德尔随机化研究。
EClinicalMedicine. 2020 Feb 19;21:100280. doi: 10.1016/j.eclinm.2020.100280. eCollection 2020 Apr.
3
JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate.普通人群中的JAK2V617F体细胞突变：骨髓增殖性肿瘤的发生发展及进展速率
Haematologica. 2014 Sep;99(9):1448-55. doi: 10.3324/haematol.2014.107631. Epub 2014 Jun 6.
4
Tocilizumab and soluble interleukin-6 receptor in V617F somatic mutation and myeloproliferative neoplasm.托珠单抗与可溶性白细胞介素-6受体在V617F体细胞突变和骨髓增殖性肿瘤中的作用
EClinicalMedicine. 2020 May 3;22:100337. doi: 10.1016/j.eclinm.2020.100337. eCollection 2020 May.
5
JAK2V617F mutation in patients with splanchnic vein thrombosis.JAK2V617F 突变与肠系膜静脉血栓形成。
Dig Dis Sci. 2010 Jun;55(6):1770-7. doi: 10.1007/s10620-009-0933-y. Epub 2009 Aug 19.
6
Enhanced Risk for Specific Somatic Myeloproliferative Neoplastic Mutations in Patients with Stroke.中风患者特定体细胞骨髓增殖性肿瘤突变的风险增加。
Curr Neurovasc Res. 2017;14(3):222-231. doi: 10.2174/1567202614666170619082900.
7
Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN).马来西亚经典骨髓增殖性肿瘤（MPN）患者 JAK2 V617F、CALR 和 MPL 突变的临床和实验室特征。
Int J Environ Res Public Health. 2021 Jul 16;18(14):7582. doi: 10.3390/ijerph18147582.
8
[Progress of study on JAK2V617F mutation in myeloproliferative neoplasm].[骨髓增殖性肿瘤中JAK2V617F突变的研究进展]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Oct;19(5):1329-33.
9
Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm.在骨髓增殖性肿瘤的小鼠模型中，内皮细胞JAK2V617F突变会导致血栓形成、血管病变和心肌病。
J Thromb Haemost. 2020 Dec;18(12):3359-3370. doi: 10.1111/jth.15095. Epub 2020 Oct 5.
10
Quantification of JAK2V617F mutation load by droplet digital PCR can aid in diagnosis of myeloproliferative neoplasms.通过液滴数字 PCR 定量 JAK2V617F 突变负荷有助于骨髓增殖性肿瘤的诊断。
Int J Lab Hematol. 2021 Aug;43(4):645-650. doi: 10.1111/ijlh.13560. Epub 2021 May 11.
引用本文的文献
1
Tocilizumab and soluble interleukin-6 receptor in V617F somatic mutation and myeloproliferative neoplasm.托珠单抗与可溶性白细胞介素-6受体在V617F体细胞突变和骨髓增殖性肿瘤中的作用
EClinicalMedicine. 2020 May 3;22:100337. doi: 10.1016/j.eclinm.2020.100337. eCollection 2020 May.
本文引用的文献
1
Loss-of-function polymorphism in reduces risk of V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study.中的功能丧失多态性降低V617F体细胞突变和骨髓增殖性肿瘤的风险：一项孟德尔随机化研究。
EClinicalMedicine. 2020 Feb 19;21:100280. doi: 10.1016/j.eclinm.2020.100280. eCollection 2020 Apr.
2
The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes.白细胞介素 6 中和的 sIL-6R-sgp130 缓冲系统在 2 型糖尿病患者中受到干扰。
Am J Physiol Endocrinol Metab. 2019 Aug 1;317(2):E411-E420. doi: 10.1152/ajpendo.00166.2019. Epub 2019 Jun 25.
3
Interleukin-6: designing specific therapeutics for a complex cytokine.白细胞介素 6：为复杂细胞因子设计特异性治疗药物。
Nat Rev Drug Discov. 2018 Jun;17(6):395-412. doi: 10.1038/nrd.2018.45. Epub 2018 May 4.
4
The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases.白细胞介素-6受体Asp358Ala单核苷酸多态性rs2228145使ADAM蛋白酶的蛋白水解转化率增加。
Biochim Biophys Acta. 2014 Sep;1842(9):1485-94. doi: 10.1016/j.bbadis.2014.05.018. Epub 2014 May 27.
5
Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced.白细胞介素-6受体（IL-6R）基因多态性：有力证据表明可溶性IL-6R的血清水平受遗传因素影响。
Genes Immun. 2004 Sep;5(6):513-6. doi: 10.1038/sj.gene.6364120.
Zotero 插件